Published online May 27, 2024. doi: 10.4240/wjgs.v16.i5.1436
Revised: April 10, 2024
Accepted: April 22, 2024
Published online: May 27, 2024
Processing time: 140 Days and 2.4 Hours
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare type of non-small-cell lung cancer. Stomach lymphoepithelioma-like carcinoma (LELC) me
A 64-year-old female was admitted to our hospital for a regular gastroscopy examination with a 6-year history of surgical resection for left PLELC. Positron emission tomography/computed tomography suggested high accumulation of 18F-fludeoxyglucose in the gastric cardia region. Upper gastrointestinal endo
For gastric LELC metastasis, PD-1 inhibitor therapy could become a new therapeutic approach, though there is still no evidence from large data sets to support this.
Core Tip: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare type of non-small-cell lung cancer. Stomach lymphoepithelioma-like carcinoma (LELC) metastasis secondary to PLELC has not been reported recently. We present a 64-year-old female patient who was admitted to our hospital for a regular gastroscopy examination with a 6-year history of surgical resection for left PLELC. After proximal gastrectomy, histopathological examination showed a poorly differentiated carcinoma with prominent lymphoplasmacytic infiltration, suggesting stomach LELC metastasis. Tumor programmed cell death ligand 1 (PD-L1) expression showed a tumor proportion score of 98% and a combined positive score of 100. After discharge, this patient underwent PD-1 inhibitor treatment for ten cycles and has not experienced tumor recurrence. These findings suggest that for gastric LELC metastasis, PD-1 inhibitor therapy could become a potential therapeutic approach.